Jaguar Health (JAGX) Depreciation and Depletion (2016 - 2017)
Jaguar Health (JAGX) reported Depreciation and Depletion of $15031.0 for Q3 2017, little changed year-over-year from $15031.0 in Q3 2016, and little changed quarter-over-quarter from $15031.0 in Q3 2016.
Jaguar Health (JAGX) Depreciation and Depletion (2016 - 2017) Analysis & Trends
Jaguar Health (JAGX) has 2 years of Depreciation and Depletion data on file, last reported at $15031.0 in Q3 2017.
- Depreciation and Depletion for Q3 2017 came in at $15031.0, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2017 was $43198.0 (up 53.36% YoY), and the FY2015 annual result was $4379.0, changed N/A from the prior year.
- Depreciation and Depletion was little changed at $15031.0 in Q3 2017 per JAGX's latest filing, from $15031.0 in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $15031.0 in Q3 2016 and troughed at $6568.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 15,031.00 |
| Sep 30, 2017 | 15,031.00 |
| Sep 30, 2016 | 15,031.00 |
| Sep 30, 2016 | 15,031.00 |
| Jun 30, 2016 | 6,568.00 |
| Jun 30, 2016 | 6,568.00 |
| Mar 31, 2016 | 6,568.00 |
| Mar 31, 2016 | 6,568.00 |